The use of expanded eligibility criteria would allow nearly twice as many people with non-small cell lung cancer to participate in clinical trials, according to data presented at ASCO Annual Meeting. The study is the result of a joint project between ASCO and the nonprofit advocacy group Friends of Cancer Research, which issued recommendations for expanding clinical trial access. The retrospective study of 10,500 NSCLC patients used Real-World Data and analysis from ConcertAI.